氯吡哌醇 T13580

Product Introduction
Bioactivity


英文名: Bimoclomol

描述: Bimoclomol is a heat shock protein co-inducer used for the research of cardiovascular diseases.

体外活性: Bimoclomol significantly increases LVDP and CO, but it decreases LVEDP under ischemic conditions. Bimoclomol (40 μM) significantly increases coronary flow (CF) in the period of normoxic perfusion (before ischemia). Bimoclomol displays a biphasic effect on the rate of relaxation. Bimoclomol (>10 μM) causes concentration-dependent vasorelaxation (EC50: 214 μM). Bimoclomol (100 μM) induces vasorelaxation also against 20 mM KCl. However, bimoclomol fails to relax preparations precontracted with serotonin, PGF2, or angiotensin II [1]. Bimoclomol does not affect the stability of Hsp70 or its mRNA. Bimoclomol co-induces Hsp expression via the prolonged activation of the HSF-1. The effects of bimoclomol are abolished in cells from mice lacking HSF-1. Furthermore, bimoclomol can bind to HSF-1 and induce a prolonged binding of HSF-1 to the respective DNA elements [2]. Bimoclomol (0.1, 1, and 10 μM) improves cell survival of rat neonatal cardiomyocytes compared to vehicle-treated cells. Bimoclomol (0.01 to 10 μM) significantly elevates HSP70 levels, based on the time of exposure. Pretreatment with bimoclomol for 24 h significantly increases the survival of cells [3].

体内活性: In anesthetized dogs, Bimoclomol (1 and 5 mg/kg) decreases the ST-segment elevation induced by coronary occlusion by 56% and 80%, respectively [1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: Bimoclomol

氯吡哌醇 T13580信息由TargetMol中国为您提供，如您想了解更多关于氯吡哌醇 T13580报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途